Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome
- PMID: 18505764
- PMCID: PMC2515084
- DOI: 10.1210/jc.2008-0287
Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome
Abstract
Context: When used for ovulation induction, higher doses of clomiphene may lead to antiestrogenic side effects that reduce fecundity. It has been suggested that metformin in combination with clomiphene can restore ovulation to some clomiphene-resistant anovulators with polycystic ovary syndrome (PCOS).
Objective: Our objective was to determine if cotreatment with extended-release metformin (metformin XR) can lower the threshold dose of clomiphene needed to induce ovulation in women with PCOS.
Design: A secondary analysis of data from the National Institute of Child Health and Human Development Cooperative Multicenter Reproductive Medicine Network prospective, double-blind, placebo-controlled multicenter clinical trial, Pregnancy in Polycystic Ovary Syndrome, was performed.
Setting: Study volunteers at multiple academic medical centers were included.
Participants: Women with PCOS and elevated serum testosterone who were randomized to clomiphene alone or with metformin (n = 209 in each group) were included in the study.
Interventions: Clomiphene citrate, 50 mg daily for 5 d, was increased to 100 and 150 mg in subsequent cycles if ovulation was not achieved; half also received metformin XR, 1000 mg twice daily. Treatment was for up to 30 wk or six cycles, or until first pregnancy.
Main outcome measures: Ovulation was confirmed by a serum progesterone more than or equal to 5 ng/ml, drawn prospectively every 1-2 wk.
Results: The overall prevalence of at least one ovulation after clomiphene was 75 and 83% (P = 0.04) for the clomiphene-only and clomiphene plus metformin groups, respectively. Using available data from 314 ovulators, the frequency distribution of the lowest clomiphene dose (50, 100, or 150 mg daily) resulting in ovulation was indistinguishable between the two treatment groups.
Conclusion: Metformin XR does not reduce the lowest dose of clomiphene that induces ovulation in women with PCOS.
Similar articles
-
Antimüllerian hormone level predicts ovulation in women with polycystic ovary syndrome treated with clomiphene and metformin.Fertil Steril. 2024 Apr;121(4):660-668. doi: 10.1016/j.fertnstert.2023.12.031. Epub 2023 Dec 26. Fertil Steril. 2024. PMID: 38154770 Free PMC article. Clinical Trial.
-
Combined metformin and clomiphene citrate versus highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial.Gynecol Endocrinol. 2011 Mar;27(3):190-6. doi: 10.3109/09513590.2010.488771. Epub 2010 Jun 23. Gynecol Endocrinol. 2011. Retraction in: Gynecol Endocrinol. 2024 Dec;40(1):2272094. doi: 10.1080/09513590.2023.2272094. PMID: 20568955 Retracted. Clinical Trial.
-
Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial.Gynecol Endocrinol. 2018 Apr;34(4):298-300. doi: 10.1080/09513590.2017.1395838. Epub 2017 Oct 27. Gynecol Endocrinol. 2018. Retraction in: Gynecol Endocrinol. 2024 Dec;40(1):2349424. doi: 10.1080/09513590.2024.2349424. PMID: 29076376 Retracted. Clinical Trial.
-
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.Fertil Steril. 2006 Nov;86(5):1432-7. doi: 10.1016/j.fertnstert.2006.06.014. Epub 2006 Sep 27. Fertil Steril. 2006. PMID: 17007847 Review.
-
Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents.Fertil Steril. 2010 Dec;94(7):2659-64. doi: 10.1016/j.fertnstert.2010.03.077. Epub 2010 May 7. Fertil Steril. 2010. PMID: 20451181 Free PMC article. Review.
Cited by
-
Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome.Hum Reprod. 2010 Oct;25(10):2612-21. doi: 10.1093/humrep/deq210. Epub 2010 Aug 17. Hum Reprod. 2010. PMID: 20716558 Free PMC article.
-
Update on the therapeutic role of metformin in the management of polycystic ovary syndrome: Effects on pathophysiologic process and fertility outcomes.Womens Health (Lond). 2025 Jan-Dec;21:17455057241311759. doi: 10.1177/17455057241311759. Womens Health (Lond). 2025. PMID: 39899277 Free PMC article. Review.
-
Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches.P T. 2013 Jun;38(6):336-55. P T. 2013. PMID: 23946629 Free PMC article.
-
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6. Cochrane Database Syst Rev. 2017. PMID: 29183107 Free PMC article.
-
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2019 Dec 17;12(12):CD013505. doi: 10.1002/14651858.CD013505. Cochrane Database Syst Rev. 2019. PMID: 31845767 Free PMC article.
References
-
- Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 377–384
-
- Ehrmann DA 2005 Polycystic ovary syndrome. N Engl J Med 352:1223–1236 - PubMed
-
- Homburg R 2005 Clomiphene citrate–end of an era? A mini-review. Hum Reprod 20:2043–2051 - PubMed
-
- Mor E, Zograbyan A, Saadat P, Bayrak A, Tourgeman DE, Zhang C, Stanczyk FZ, Paulson RJ 2004 The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis. Am J Obstet Gynecol 190:1654–1660 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 HD038988/HD/NICHD NIH HHS/United States
- U10 HD039005/HD/NICHD NIH HHS/United States
- M01 RR010732/RR/NCRR NIH HHS/United States
- U10 HD27049/HD/NICHD NIH HHS/United States
- C06 RR016499/RR/NCRR NIH HHS/United States
- U10 HD038998/HD/NICHD NIH HHS/United States
- U54-HD29834/HD/NICHD NIH HHS/United States
- U10 HD38992/HD/NICHD NIH HHS/United States
- U10 HD038999/HD/NICHD NIH HHS/United States
- U10 HD033172/HD/NICHD NIH HHS/United States
- R01 HD029834/HD/NICHD NIH HHS/United States
- U10 HD027049/HD/NICHD NIH HHS/United States
- U10 HD27011/HD/NICHD NIH HHS/United States
- U10 HD027011/HD/NICHD NIH HHS/United States
- U01 HD38997/HD/NICHD NIH HHS/United States
- M01RR10732/RR/NCRR NIH HHS/United States
- U10 HD38998-9/HD/NICHD NIH HHS/United States
- U10 HD33172/HD/NICHD NIH HHS/United States
- M01 RR000056/RR/NCRR NIH HHS/United States
- U10 HD39005/HD/NICHD NIH HHS/United States
- U10 HD038992/HD/NICHD NIH HHS/United States
- U01 HD038997/HD/NICHD NIH HHS/United States
- M01RR00056/RR/NCRR NIH HHS/United States
- U10 HD38988/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical